Affimed Presents Preclinical Data on Lead Candidate AFM13 at the Annual Meeting of the Society for Natural Immunity
October 04 2016 - 5:00AM
Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical
company focused on discovering and developing highly targeted
cancer immunotherapies, announced today the presentation of
preclinical data on the Company’s lead candidate AFM13, a
bispecific NK-cell-engaging TandAb targeting CD30/CD16A, at the
16th Annual Meeting of the Society for Natural Immunity in
Taormina, Italy.
The data, generated in Affimed’s collaboration
with the Innate Immunity Group of Dr. Adelheid Cerwenka at the
German Cancer Research Center (DKFZ) in Heidelberg, Germany, were
presented in a poster titled “The bispecific CD30/CD16A TandAb
AFM13 amplifies the cytolytic and proliferative potential of
NK-cells” yesterday, October 3, 2016.
In this preclinical study, the specific
phenotype and functionality of human NK-cells when redirected to
AFM13-coated tumor cells, as well as their responsiveness to
cytokines, were analyzed. The results show that AFM13 improves
NK-cell cytotoxicity against CD30+ tumor cells that are resistant
to naïve NK-cells. Using CFSE-labelled NK-cells, the researchers
demonstrated that AFM13 amplifies cytokine–mediated NK-cell
proliferation and expansion by enhancing the NK-cells’ sensitivity
to IL-2 and IL-15. These data indicate that cytokine administration
in combination with AFM13 might potentially enhance NK-cell
activity in the tumor microenvironment.
AFM13 is a tetravalent bispecific TandAb
antibody that binds bivalently to both CD30 on tumor cells and
CD16A on NK-cells. The molecule has been shown to engage NK-cells
through CD16A with high affinity and specificity, resulting in
strong NK-cell-mediated cytotoxicity. AFM13 is currently being
tested in Hodgkin lymphoma patients as a monotherapy (Phase 2) and
in combination with Merck’s Keytruda® (Phase 1b).
About Affimed N.V.
Affimed (Nasdaq:AFMD) engineers targeted
immunotherapies, seeking to cure patients by harnessing the power
of innate and adaptive immunity (NK- and T-cells). We are
developing single and combination therapies to treat cancers and
other life-threatening diseases. For more information, please visit
www.affimed.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as "anticipate," "believe," "could," "estimate," "expect,"
"goal," "intend," "look forward to", "may," "plan," "potential,"
"predict," "project," "should," "will," "would" and similar
expressions. Forward-looking statements appear in a number of
places throughout this release and include statements regarding our
intentions, beliefs, projections, outlook, analyses and current
expectations concerning, among other things, our ongoing and
planned preclinical development and clinical trials, our
collaborations and development of our products in combination with
other therapies, the timing of and our ability to make regulatory
filings and obtain and maintain regulatory approvals for our
product candidates our intellectual property position, our
collaboration activities, our ability to develop commercial
functions, expectations regarding clinical trial data, our results
of operations, cash needs, financial condition, liquidity,
prospects, future transactions, growth and strategies, the industry
in which we operate, the trends that may affect the industry or us
and the risks uncertainties and other factors described under the
heading “Risk Factors” in Affimed’s filings with the Securities and
Exchange Commission. Given these risks, uncertainties and other
factors, you should not place undue reliance on these
forward-looking statements, and we assume no obligation to update
these forward-looking statements, even if new information becomes
available in the future.
IR Contact:
Caroline Stewart, Head IRPhone: +1 347394 6793E-Mail:
IR@affimed.com or c.stewart@affimed.com
Media Contact:
Anca Alexandru, Head of Communications, EU IRPhone: +49 6221
64793341E-Mail: a.alexandru@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024